Date	e:2022/7	7/3						
	r Name: Jix							
Man	uscript Title: Anti-	PD-1 antibodies plus lei	nvatinib in patients with unresectable					
hep	nepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world							
pati	ients							
Man	uscript number (if know	n):						
relat parti to tr	ted to the content of you ies whose interests may ansparency and does no	r manuscript. "Related" mea be affected by the content o	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment lf you are in doubt about whether to list a so.					
	following questions appl uscript only.	y to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>					
to th	ne epidemiology of hyper		defined broadly. For example, if your manuscript pertai all relationships with manufacturers of antihypertensive he manuscript.					
	em #1 below, report all s time frame for disclosure		d in this manuscript without time limit. For all other ite	:ms,				
		Name all entities with	Specifications/Comments					
		whom you have this	(e.g., if payments were made to you or to your					
			institution)					
		-	al planning of the work					
1	All support for the present							
	manuscript (e.g., funding,							
	provision of study material	S,						
	- -							
1		relationship or indicate none (add rows as needed) Time frame: Since the initional inition	institution)					

Time frame: past 36 months

X__None

X__None

X__None

No time limit for this item.

Grants or contracts from

in item #1 above).
Royalties or licenses

Consulting fees

any entity (if not indicated

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	ntlict of interest in the f	ollowing box:

None			

Date:	2022/7/3	
	Peixin Huang	
		nvatinib in patients with unresectable
		envatinib: a retrospective cohort study of real-wor
patients		-
Manuscript number	er (if known):	
related to the cont parties whose inte to transparency ar	tent of your manuscript. "Related" mea erests may be affected by the content o	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a poso.
The following ques	stions apply to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to the epidemiolog		defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	report all support for the work reporte disclosure is the past 36 months.	d in this manuscript without time limit. For all other items,
	Name all entities with	Specifications/Comments

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	ntlict of interest in the f	ollowing box:

None			

Dat	e:2022/7/3	3						
	r Name: Ning							
Maı	nuscript Title: Anti-PI	0-1 antibodies plus len	vatinib in patients with unresectable					
hep	hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world							
-	ients	. 0	•					
Maı	Manuscript number (if known):							
rela part to t rela	ted to the content of your r ties whose interests may be ransparency and does not n tionship/activity/interest, i	manuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do						
	tollowing questions apply to the state of th	to the author's relationship	os/activities/interests as they relate to the <u>current</u>					
to t		nsion, you should declare	lefined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensivene manuscript.					
	em #1 below, report all sup time frame for disclosure is	-	l in this manuscript without time limit. For all other ite	ms,				
		Name all entities with	Specifications/Comments					
		whom you have this	(e.g., if payments were made to you or to your					
		relationship or indicate	institution)					
		none (add rows as						
		needed)						
		Time frame: Since the initia	l planning of the work					
1	All support for the present	XNone						
	manuscript (e.g., funding,							

Time frame: past 36 months

X None

_X__None

_X__None

provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

Grants or contracts from

in item #1 above).
Royalties or licenses

Consulting fees

any entity (if not indicated

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	ntlict of interest in the f	ollowing box:

None			

Dat	e:2022/	7/3	
You	r Name: Xi	n Xu	
Maı	nuscript Title: Anti-	-PD-1 antibodies plus le	nvatinib in patients with unresectable
hep	patocellular carcinoi	na who progressed on le	envatinib: a retrospective cohort study of real-world
pat	ients		
Maı	nuscript number (if knov	vn):	
rela part to t	ted to the content of your ties whose interests may ransparency and does no	ur manuscript. "Related" me be affected by the content o	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions app nuscript only.	ly to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to t med	he epidemiology of hype dication, even if that me	ertension, you should declare dication is not mentioned in a support for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the presen manuscript (e.g., funding, provision of study materia medical writing, article processing charges, etc.)		
	No time limit for this iten	n.	

Time frame: past 36 months

X__None

X__None

X__None

Grants or contracts from

in item #1 above).

Royalties or licenses

Consulting fees

any entity (if not indicated

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	ntlict of interest in the f	ollowing box:

None			

Date:	2022/7/3	
Your Name:	Yanhong	Wang
Manuscript Title:_	Anti-PD-1 ar	ntibodies plus lenvatinib in patients with unresectable
hepatocellular	carcinoma who	progressed on lenvatinib: a retrospective cohort study of real-world
patients		
In the interest of t	**************************************	lk you to disclose all relationships /activities /interests listed helaw that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
_	educational events	V. Nana		
6	Payment for expert testimony	XNone		
	testimony			
7	Support for attending	X None		
,	meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid	V. Name		
11	Stock or stock options	XNone		
12	Receipt of equipment,	X None		
12	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
_				
Plea	Please summarize the above conflict of interest in the following box:			

N	one	

Date:	2022/7/3	
Your Name:	Lan Zhang	
Manuscript Tit	tle: Anti-PD-1 ant	ibodies plus lenvatinib in patients with unresectable
hepatocellu	lar carcinoma who p	rogressed on lenvatinib: a retrospective cohort study of real-world
patients		
Manuscript nu	ımber (if known):	
In the interest	of transparency, we ask	you to disclose all relationships/activities/interests listed below that are
related to the	content of your manuscri	ipt. "Related" means any relation with for-profit or not-for-profit third
parties whose	interests may be affected	d by the content of the manuscript. Disclosure represents a commitment
to transparen	cy and does not necessari	ly indicate a bias. If you are in doubt about whether to list a
relationship/a	ctivity/interest, it is prefe	erable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	X None	Statisting of the Work
1	manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
_	educational events	V. Nana		
6	Payment for expert testimony	XNone		
	testimony			
7	Support for attending	X None		
,	meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid	V. Name		
11	Stock or stock options	XNone		
12	Receipt of equipment,	X None		
12	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
_				
Plea	Please summarize the above conflict of interest in the following box:			

N	one	

Date	:2022/7/	3		
		hen		
			vatinib in patients with unresectable	
		-	nvatinib: a retrospective cohort study of real-v	vorld
-	ents	1 0	1	
		·		
relate partie to tra	ed to the content of your es whose interests may be ansparency and does not r	manuscript. "Related" mear e affected by the content of	elationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a so.	
	following questions apply uscript only.	to the author's relationship	s/activities/interests as they relate to the <u>current</u>	
to th	e epidemiology of hyperte		efined broadly. For example, if your manuscript pertain Ill relationships with manufacturers of antihypertensive Ie manuscript.	
	m #1 below, report all sup ime frame for disclosure is	•	in this manuscript without time limit. For all other iten	ns,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as needed)		
		Time frame: Since the initial	planning of the work	

Time frame. Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	^None	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	,		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Please summarize the above conflict of interest in the following box:

None			

Please place an "X" next to the following statement to indicate your agreement: